No Data
No Data
No Data
No Data
No Data
Biotricity Announces High Demand For Its LBiotres Pro, a 3-Channel Patch-like ECG, Biotres Pro Is Expected To Raise The Average Subscription Price By Over 32%, Translating To Revenue Increase Of Up To 10% From Sales To Existing Customers Throughout 2025
Biotres Pro Is Also Capturing The Attention Of New Customers. The Initial Production Run Of Biotres Pro Has Sold Out, With Customers Placing Pre-orders For The Next Run, Which Is Scheduled To Ship To
BenzingaApr 26 19:29
Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest From Existing and New Customers
REDWOOD CITY, CA / ACCESSWIRE / April 26, 2024 / Biotricity Inc. (NASDAQ:BTCY), a pioneering Technology-as-a-Service (TaaS) company dedicated to delivering top-of-the-line medical diagnostic and consu
AccesswireApr 26 19:00
Top Premarket Decliners
Air Industries Group (AIRI) shares slumped nearly 60% Friday premarket, adding to Thursday's slide. Sunshine Biopharma (SBFM) shares were down nearly 18%, extending losses from the previous session. E
MT NewswiresApr 19 19:40
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announc
AccesswireApr 18 19:00
Biotricity Launches Cardiac Monitoring Pilot Program With Major Hospital Network
REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic
AccesswireApr 16 19:00
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
BenzingaApr 16 02:11
No Data
No Data